Septic arthritis medical therapy: Difference between revisions
Line 794: | Line 794: | ||
</div> | </div> | ||
<div class="mw-customtoggle- | <div class="mw-customtoggle-table26" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D;border-bottom: 0px;; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Aspergillus''''' | ▸ '''''Aspergillus''''' | ||
Line 800: | Line 800: | ||
</div> | </div> | ||
<div class="mw-customtoggle- | <div class="mw-customtoggle-table27" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Blastomyces''''' | ▸ '''''Blastomyces''''' | ||
Line 808: | Line 808: | ||
<div class="mw-customtoggle-table28" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | <div class="mw-customtoggle-table28" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Candida''''' | ▸ '''''Candida spp.''''' | ||
</font> | </font> | ||
</div> | </div> | ||
<div class="mw-customtoggle- | <div class="mw-customtoggle-table29" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Coccidioides''''' | ▸ '''''Coccidioides''''' | ||
Line 818: | Line 818: | ||
</div> | </div> | ||
<div class="mw-customtoggle- | <div class="mw-customtoggle-table30" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Histoplasma''''' | ▸ '''''Histoplasma''''' | ||
Line 824: | Line 824: | ||
</div> | </div> | ||
<div class="mw-customtoggle- | <div class="mw-customtoggle-table31" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 300px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''''Sporothrix''''' | ▸ '''''Sporothrix''''' | ||
Line 831: | Line 831: | ||
| valign=top | | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table26" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Aspergillus''}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Loading Dose | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Voriconazole]] 6 mg/kg IV q12h for 24 h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Maintenance Dose | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Voriconazole]] 4 mg/kg IV or 200 mg PO q12h for 9 months''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Liposomal Amphotericin B]] 3-5 mg/kg/day IV ''''' <br> OR <br> ▸ '''''[[Amphotericin B lipid complex]] 5 mg/kg/day IV ''''' <br> OR <br>▸ '''''[[Caspofungin]] 70 mg IV loading dose, then 50 mg q24h''''' <br> OR <br> ▸ '''''[[Micafungin]] 100-150 mg IV q24h '''''<br> OR <br> ▸ '''''[[Itraconazole]] 600 mg/day for 3 days, then 400 mg/day''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2008; 46:327–60''<ref name="WalshAnaissie2008">{{cite journal|last1=Walsh|first1=Thomas J.|last2=Anaissie|first2=Elias J.|last3=Denning|first3=David W.|last4=Herbrecht|first4=Raoul|last5=Kontoyiannis|first5=Dimitrios P.|last6=Marr|first6=Kieren A.|last7=Morrison|first7=Vicki A.|last8=Segal|first8=Brahm H|last9=Steinbach|first9=William J.|last10=Stevens|first10=David A.|last11=Burik|first11=Jo‐Anne van|last12=Wingard|first12=John R.|last13=Patterson|first13=Thomas F.|title=Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America|journal=Clinical Infectious Diseases|volume=46|issue=3|year=2008|pages=327–360|issn=1058-4838|doi=10.1086/525258}}</ref> | |||
</SMALL> | |||
|- | |||
|} | |||
|} | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Blastomyces}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 400 mg/day for at least 12 months''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2008;46(12):1801-12.''<ref name="Chapman-2008">{{Cite journal | last1 = Chapman | first1 = SW. | last2 = Dismukes | first2 = WE. | last3 = Proia | first3 = LA. | last4 = Bradsher | first4 = RW. | last5 = Pappas | first5 = PG. | last6 = Threlkeld | first6 = MG. | last7 = Kauffman | first7 = CA. | title = Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. | journal = Clin Infect Dis | volume = 46 | issue = 12 | pages = 1801-12 | month = Jun | year = 2008 | doi = 10.1086/588300 | PMID = 18462107 }}</ref></SMALL> | |||
|- | |||
|} | |||
|} | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table28" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table28" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Candida''}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Candida spp.''}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | ||
Line 852: | Line 890: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400mg PO q24h to complete a total duration of therapy of 6 weeks.''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400mg PO q24h to complete a total duration of therapy of 6 weeks.''''' | ||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2009;48(5):503-35.''<ref name="Pappas-2009">{{Cite journal | last1 = Pappas | first1 = PG. | last2 = Kauffman | first2 = CA. | last3 = Andes | first3 = D. | last4 = Benjamin | first4 = DK. | last5 = Calandra | first5 = TF. | last6 = Edwards | first6 = JE. | last7 = Filler | first7 = SG. | last8 = Fisher | first8 = JF. | last9 = Kullberg | first9 = BJ. | title = Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal = Clin Infect Dis | volume = 48 | issue = 5 | pages = 503-35 | month = Mar | year = 2009 | doi = 10.1086/596757 | PMID = 19191635 }}</ref></SMALL> | |||
|- | |- | ||
|} | |} | ||
|} | |} | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible- | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table29" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| }} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Coccidioides }} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 400 mg/day for at least 12 months''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 400 mg/day for at least 12 months''''' | ||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2005;41(9):1217-23.''<ref name="Galgiani-2005">{{Cite journal | last1 = Galgiani | first1 = JN. | last2 = Ampel | first2 = NM. | last3 = Blair | first3 = JE. | last4 = Catanzaro | first4 = A. | last5 = Johnson | first5 = RH. | last6 = Stevens | first6 = DA. | last7 = Williams | first7 = PL. | title = Coccidioidomycosis. | journal = Clin Infect Dis | volume = 41 | issue = 9 | pages = 1217-23 | month = Nov | year = 2005 | doi = 10.1086/496991 | PMID = 16206093 }}</ref></SMALL> | |||
|- | |||
|} | |} | ||
|} | |} | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible- | |||
| valign=top | | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table30" style="background: #FFFFFF;" | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | | valign=top |{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|'' | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|''Histoplasma capsulatum''}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''Preferred Regimen''' | ||
|- | |- | ||
| style=" | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Liposomal Amphotericin B]] 5 mg/kg IV q24h for 4—6 weeks''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | FOLLOWED BY | ||
|- | |- | ||
| style=" | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 200 mg PO bid—tid for ≥12 months''''' | ||
|- | |- | ||
| style="font-size: 90% | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL>Adapted from ''Clin Infect Dis. 2007;45(7):807-25.''<ref name="Wheat-2007">{{Cite journal | last1 = Wheat | first1 = LJ. | last2 = Freifeld | first2 = AG. | last3 = Kleiman | first3 = MB. | last4 = Baddley | first4 = JW. | last5 = McKinsey | first5 = DS. | last6 = Loyd | first6 = JE. | last7 = Kauffman | first7 = CA. | title = Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. | journal = Clin Infect Dis | volume = 45 | issue = 7 | pages = 807-25 | month = Oct | year = 2007 | doi = 10.1086/521259 | PMID = 17806045 }}</ref></SMALL> | ||
|- | |- | ||
| style=" | |} | ||
|} | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table31" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Sporothrix}} | |||
|- | |- | ||
| style="font-size: 90%; | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Itraconazole]] 400 mg/day for at least 12 months''''' | |||
|} | |||
|} | |||
|} | |} | ||
|} | |} |
Revision as of 16:14, 22 May 2014
Septic arthritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Septic arthritis medical therapy On the Web |
American Roentgen Ray Society Images of Septic arthritis medical therapy |
Risk calculators and risk factors for Septic arthritis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Jumana Nagarwala, M.D., Senior Staff Physician, Department of Emergency Medicine, Henry Ford Hospital; Cafer Zorkun, M.D., Ph.D. [2]
Overview
The treatment for septic arthritis requires an adequate drainage of the joint fluid and appropriate antibiotic therapy. Empiric therapy should be started after the collection joint fluid and blood sample for culture. There are no indications for intra-articular antibiotic therapy.
Medical Therapy
Antibiotics are used to treat the infection and most of them achieve excellent bactericidal concentrations in the synovial fluid. The initial therapy depends on the clinical presentation, whether the patient is at risk for a Gonoccocal infection or not, and Gram stain of joint aspiration. The final therapy depends on the culture and sensitivity results. During the acute phase of the disease is important to keep the the joint still and raised, and the patient need to rest. Using cool compresses may help relieve pain. After the acute phase, exercise and physical therapy is important for the recovery process. Severe cases may need surgery to drain the infected joint fluid.
Duration of Antimicrobial Therapy
- The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
Microorganism | Duration of Therapy |
▸ Staphylococcus aureus | 3-4 weeks |
▸ Streptococcus groups A, B, C, G | 3-4 weeks |
▸ Gram-negative bacilli | 4 weeks |
▸ Brucella | 6 weeks |
▸ Borrelia burgdorferi | 30 days |
▸ Mycobacterium tuberculosis | 9 months |
▸ Candida albicans | 6 weeks |
Special cases | Duration of Therapy |
▸ Prosthetic joint infection | 6 weeks |
▸ Post intra-articular injection or post-arthroscopy infection | 14 days |
Empiric Therapy Adapted from Lancet 375:846, 2010.[1]
▸ Click on the following categories to expand treatment regimens.
Pediatric Newborns (< 1 week) ▸ Newborns (1 -4 week) ▸ Infants (1 - 3 months) ▸ Children (3 mo - 14 yr) Adults ▸ Acute Monoarticular ▸ Chronic Monoarticular ▸ Polyarticular |
|
Synovial Fluid Gram Stain-Based Therapy Adapted from Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases[2]
▸ Click on the following categories to expand treatment regimens.
Gram-Positive ▸ Gram-Positive Cocci ▸ Gram-Positive Bacilli Gram-Negative ▸ Gram-Negative Cocci ▸ Gram-Negative Rods ▸ Negative Gram Stain |
|
Pathogen-Based Therapy — Bacteria Adapted from Bacterial septic arthritis in adults.[3] and CLIN. MICROBIOL. REV. Acute Septic Arthritis [4]
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ Brucella ▸ E. coli ▸ Enterococcus spp. ▸ Haemophilus influenzae ▸ Neisseria gonorrhoeae ▸ Proteus mirabilis ▸ Pseudomonas aeruginosa ▸ Staphylococcus aureus ▸ Staphylococcus epidermidis ▸ Streptococcus groups A, B, C, G ▸ T. whipplei Mycobacteria ▸ Mycobacterium tuberculosis Spirochetes ▸ Borrelia burgdorferi ▸ Treponema pallidum |
|
Pathogen-Based Therapy — Fungi
▸ Click on the following categories to expand treatment regimens.
Fungi ▸ Aspergillus ▸ Blastomyces ▸ Candida spp. ▸ Coccidioides ▸ Histoplasma ▸ Sporothrix |
|
|
|} |} |}
Pathogen-Based Therapy — Virus
The treatment for viral arthritis is symptomatic, with the use of analgesics and NSAID. No antimicrobial therapy is recommended for treating arthritis caused by a virus.[16][17]
Vaccination and safe sex are the most important measures to avoid viral infections in the joint.
Pathogen-Based Therapy in Patients with Prosthetic Joint Adapted from Diagnosis and Management of Prosthetic Joint Infection CID 2013:56[18]
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ Staphylococci, oxacillin-susceptible ▸ Staphylococci, oxacillin-resistant ▸ Enterococcus spp, penicillin-susceptible ▸ Enterococcus spp, penicillin-resistant ▸ Pseudomonas aeruginosa ▸ Enterobacter spp ▸ Enterobacteriaceae ▸ β-hemolytic streptococci ▸ Propionibacterium acnes |
|
References
- ↑ Mathews, CJ.; Weston, VC.; Jones, A.; Field, M.; Coakley, G. (2010). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–55. doi:10.1016/S0140-6736(09)61595-6. PMID 20206778. Unknown parameter
|month=
ignored (help) - ↑ Mandell, Gerald L.; Bennett, John E. (John Eugene); Dolin, Raphael. (2010). Mandell, Douglas, and Bennett's principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN [[Special:BookSources/<!DOCTYPE|<!DOCTYPE]] Check
|isbn=
value: invalid character (help). - ↑ "Bacterial septic arthritis in adults. [Lancet. 2010] - PubMed - NCBI". Retrieved 20 May 2014.
- ↑ Shirtliff, M. E.; Mader, J. T. (2002). "Acute Septic Arthritis". Clinical Microbiology Reviews. 15 (4): 527–544. doi:10.1128/CMR.15.4.527-544.2002. ISSN 0893-8512.
- ↑ Ariza, Javier; Bosilkovski, Mile; Cascio, Antonio; Colmenero, Juan D.; Corbel, Michael J.; Falagas, Matthew E.; Memish, Ziad A.; Roushan, Mohammad Reza Hasanjani; Rubinstein, Ethan; Sipsas, Nikolaos V.; Solera, Javier; Young, Edward J.; Pappas, Georgios (2007). "Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations". PLoS Medicine. 4 (12): e317. doi:10.1371/journal.pmed.0040317. ISSN 1549-1277.
- ↑ Liu, C.; Bayer, A.; Cosgrove, S. E.; Daum, R. S.; Fridkin, S. K.; Gorwitz, R. J.; Kaplan, S. L.; Karchmer, A. W.; Levine, D. P.; Murray, B. E.; Rybak, M. J.; Talan, D. A.; Chambers, H. F. (2011). "Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children". Clinical Infectious Diseases. 52 (3): e18–e55. doi:10.1093/cid/ciq146. ISSN 1058-4838.
- ↑ Treatment of tuberculosis : guidelin. Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3.
- ↑ . doi:10.1086/522848. Missing or empty
|title=
(help) - ↑ "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm". Retrieved 19 May 2014. External link in
|title=
(help) - ↑ Fenollar, Florence; Puéchal, Xavier; Raoult, Didier (2007). "Whipple's Disease". New England Journal of Medicine. 356 (1): 55–66. doi:10.1056/NEJMra062477. ISSN 0028-4793.
- ↑ Walsh, Thomas J.; Anaissie, Elias J.; Denning, David W.; Herbrecht, Raoul; Kontoyiannis, Dimitrios P.; Marr, Kieren A.; Morrison, Vicki A.; Segal, Brahm H; Steinbach, William J.; Stevens, David A.; Burik, Jo‐Anne van; Wingard, John R.; Patterson, Thomas F. (2008). "Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America". Clinical Infectious Diseases. 46 (3): 327–360. doi:10.1086/525258. ISSN 1058-4838.
- ↑ Chapman, SW.; Dismukes, WE.; Proia, LA.; Bradsher, RW.; Pappas, PG.; Threlkeld, MG.; Kauffman, CA. (2008). "Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America". Clin Infect Dis. 46 (12): 1801–12. doi:10.1086/588300. PMID 18462107. Unknown parameter
|month=
ignored (help) - ↑ Pappas, PG.; Kauffman, CA.; Andes, D.; Benjamin, DK.; Calandra, TF.; Edwards, JE.; Filler, SG.; Fisher, JF.; Kullberg, BJ. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635. Unknown parameter
|month=
ignored (help) - ↑ Galgiani, JN.; Ampel, NM.; Blair, JE.; Catanzaro, A.; Johnson, RH.; Stevens, DA.; Williams, PL. (2005). "Coccidioidomycosis". Clin Infect Dis. 41 (9): 1217–23. doi:10.1086/496991. PMID 16206093. Unknown parameter
|month=
ignored (help) - ↑ Wheat, LJ.; Freifeld, AG.; Kleiman, MB.; Baddley, JW.; McKinsey, DS.; Loyd, JE.; Kauffman, CA. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045. Unknown parameter
|month=
ignored (help) - ↑ Berner, IC.; Dudler, J. (2006). "[Viral arthritis]". Rev Med Suisse. 2 (57): 732–4, 737. PMID 16604875. Unknown parameter
|month=
ignored (help) - ↑ Märker-Hermann, E.; Schütz, N.; Bauer, H. (2010). "[Viral arthritides]". Z Rheumatol. 69 (10): 871–8. doi:10.1007/s00393-010-0701-6. PMID 21128048. Unknown parameter
|month=
ignored (help) - ↑ Osmon, D. R.; Berbari, E. F.; Berendt, A. R.; Lew, D.; Zimmerli, W.; Steckelberg, J. M.; Rao, N.; Hanssen, A.; Wilson, W. R. (2012). "Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases. 56 (1): e1–e25. doi:10.1093/cid/cis803. ISSN 1058-4838.